Want to see LTRN full AI Analyst Report?
LTRN Stock Chart & Stats
$2.18
$0.04(1.45%)
At close: 4:00 PM EDT
$2.18
$0.04(1.45%)
Day’s Range― - ―
52-Week Range$1.11 - $4.70
Previous CloseN/A
Volume2.60K
Average Volume (3M)159.65K
Market Cap
$26.97M
Enterprise Value$44.48
Total Cash (Recent Filing)$7.36M
Total Debt (Recent Filing)$39.72K
Price to Earnings (P/E)―
Beta2.39
Next Earnings
Nov 11, 2026EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.62
Shares Outstanding12,784,146
10 Day Avg. Volume114,283
30 Day Avg. Volume159,645
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)5.05
Price to Sales (P/S)0.00
P/FCF Ratio-2.11
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.51
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
AI Platform CommercializationOMAI gives Lantern a second potential business model beyond drug development, creating a path to commercial software revenue, external capital and strategic partnerships while retaining ownership of the platform.
Regulatory And IP Pipeline ProgressMultiple regulatory clearances and biomarker-related IP expand LP-184's development options and may improve partnering potential by supporting precision-treatment strategies across several solid-tumor indications.
Clinical Progress And Operating EfficiencyEncouraging early LP-300 activity supports continued investment in a defined patient subgroup, while lower R&D spending and operating losses indicate a potentially efficient approach to advancing multiple programs.
Bears Say
No Commercial Revenue And Persistent LossesWithout product revenue, Lantern remains dependent on financings, collaborations or future approvals to fund operations. Persistent losses and cash burn make the path to self-sustaining profitability uncertain.
Weak Balance Sheet And Financing DependenceNegative equity and limited liquidity reduce financial flexibility and increase reliance on additional capital. Future financings may be necessary to maintain clinical development and could occur on unfavorable terms.
Immature Clinical Evidence And Dilution RiskSmall, exploratory cohorts may not predict later-stage outcomes, so the investment case remains dependent on validation through additional enrollment. Outstanding warrants and future raises could dilute existing shareholders.
Lantern Pharma News
LTRN FAQ
What was Lantern Pharma, Inc.’s price range in the past 12 months?
Lantern Pharma, Inc. lowest stock price was $1.11 and its highest was $4.70 in the past 12 months.
What is Lantern Pharma, Inc.’s market cap?
Lantern Pharma, Inc.’s market cap is $26.97M.
When is Lantern Pharma, Inc.’s upcoming earnings report date?
Lantern Pharma, Inc.’s upcoming earnings report date is Nov 11, 2026 which is in 76 days.
How were Lantern Pharma, Inc.’s earnings last quarter?
Lantern Pharma, Inc. released its earnings results on Aug 14, 2026. The company reported -$0.57 earnings per share for the quarter, missing the consensus estimate of -$0.38 by -$0.19.
Is Lantern Pharma, Inc. overvalued?
According to Wall Street analysts Lantern Pharma, Inc.’s price is currently Overvalued.
Does Lantern Pharma, Inc. pay dividends?
Lantern Pharma, Inc. does not currently pay dividends.
What is Lantern Pharma, Inc.’s EPS estimate?
Lantern Pharma, Inc.’s EPS estimate is -0.35.
How many shares outstanding does Lantern Pharma, Inc. have?
Lantern Pharma, Inc. has 12,784,146 shares outstanding.
What happened to Lantern Pharma, Inc.’s price movement after its last earnings report?
Lantern Pharma, Inc. reported an EPS of -$0.57 in its last earnings report, missing expectations of -$0.38. Following the earnings report the stock price went up 0.76%.
Which hedge fund is a major shareholder of Lantern Pharma, Inc.?
Currently, no hedge funds are holding shares in LTRN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lantern Pharma, Inc.
Lantern Pharma Inc. is a clinical-stage biotechnology firm dedicated to revolutionizing drug development through the strategic application of artificial intelligence, machine learning, and comprehensive genomic data analysis. Their primary drug candidate, LP-100, is currently undergoing Phase II clinical trials, targeting metastatic, castration-resistant prostate cancer. The company is also advancing LP-300 as a potential combination therapy for non-small cell lung cancer adenocarcinoma, specifically in individuals who are non-smokers or have never smoked. Furthermore, their preclinical pipeline includes LP-184, an alkylating agent engineered to inflict DNA damage upon cancer cells that either overexpress specific biomarkers or exhibit mutations within their DNA repair pathways. Beyond these, Lantern Pharma maintains an antibody-drug conjugate (ADC) program for diverse cancer treatments. Central to their operations is the RADR artificial intelligence platform, which synergizes molecular data through advanced big data analytics and machine learning capabilities. Established in 2013, the company operates from its headquarters in Dallas, Texas.
LTRN Company Deck
LTRN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed significant strategic and clinical progress — multiple regulatory clearances (EMA and FDA), a valuable patient-selection patent, promising early LP-300 efficacy signals in L858R NSCLC, and the formation of Open Medicine AI as a potential high-value, standalone AI engine — all achieved with reported operating expense discipline (R&D down ~42%, loss from operations down ~25%). However, financial constraints and accounting-related volatility are notable: cash of ~$7.4M at quarter-end, a large noncash warrant expense (~$3.6M) that increased reported net loss, potential dilution from issued warrants, and immature small-size clinical cohorts that require further enrollment to confirm results. Overall, material strategic and clinical milestones are balanced by near-term funding and data-maturation risks.View all LTRN earnings summariesTechnical Analysis
Ownership Overview
1.12% Insiders
3.29% Mutual Funds
12.65% Other Institutional Investors
79.45% Public Companies and
Individual Investors